title: Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats.
abstract: Interruptions of Matrix Metalloproteinase-2 (MMP-2) and Matrix Metalloproteinase-9 (MMP-9) have been shown to reduce the ensuing threatening risk factors of vascular complications of diabetes by alteration in Extracellular Matrix (ECM). We hypothesized that minocycline induced MMP-2 and MMP-9 inhibition can be enhanced by aspirin, a non-selective COX and tPA inhibitor and this combination can reduce progression of diabetic retinopathy. Diabetes was induced in male Wistar rats by streptozotocin (55 mg/kg i.p.). Four weeks after diabetes induction rats were treated with minocycline (50 mg/kg, p.o.) per se, aspirin (50 mg/kg, p.o.) per se, or minocycline in combination with aspirin for a period of four weeks. At the end of eighth week rats were anesthetized and electroretinograms were recorded. B-wave latency, B-wave amplitude and retinal permeability were measured. Histology was done and retinal thickness was measured. Zymography was carried out for MMP-2 and MMP-9 level determinations. B-wave amplitude was significantly decreased while B- wave latency was significantly increased in diabetic group when compared with normo-glycemic rats. Treatment with combination of minocycline and aspirin significantly reversed B-wave amplitude and latency compared with vehicle-treated diabetic controls. Blood retinal permeability and retinal thickness were also significantly attenuated by the treatment of minocycline in combination with aspirin. Results of the present study suggest that MMP-2 and MMP-9 inhibition in presence of COX inhibitor prevents the development of experimental diabetic retinopathy in rats and can be a potential approach for the treatment.
authors.affiliation: Department of Pharmacology, School of Pharmacy and Technology Management, NMIMS University, Vile Parle (W) Mumbai, 400 056, India.
authors.forename: Lokesh Kumar
authors.initials: LK
authors.lastname: Bhatt
authors.forename: Veeranjaneyulu
authors.initials: V
authors.lastname: Addepalli
references.citation: J Genet. 2009 Dec;88(4):495-515
references.pmid: 20090210
references.citation: Expert Opin Investig Drugs. 2004 Oct;13(10):1275-93
references.pmid: 15461557
references.citation: FASEB J. 1992 Aug;6(11):2905-14
references.pmid: 1644256
references.citation: N Engl J Med. 1987 Mar 5;316(10):599-606
references.pmid: 3027558
references.citation: FASEB J. 1990 Apr 1;4(6):1577-90
references.pmid: 2180767
references.citation: Rev Endocr Metab Disord. 2008 Dec;9(4):315-27
references.pmid: 18654858
references.citation: Invest Ophthalmol Vis Sci. 2003 May;44(5):2163-70
references.pmid: 12714657
references.citation: Diabetologia. 1976 Aug;12(4):367-74
references.pmid: 134921
references.citation: Acta Ophthalmol Scand. 2002 Jun;80(3):305-9
references.pmid: 12059871
references.citation: Clin Cancer Res. 2003 Feb;9(2):551-4
references.pmid: 12576417
references.citation: Circ Res. 2001 Jun 22;88(12):1291-8
references.pmid: 11420306
references.citation: Invest Ophthalmol Vis Sci. 2008 Feb;49(2):732-42
references.pmid: 18235022
references.citation: Arch Ophthalmol. 1961 Sep;66:366-78
references.pmid: 13694291
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1335-45
references.pmid: 17265029
references.citation: Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):699-706
references.pmid: 19084986
references.citation: Diabet Med. 2008 May;25(5):536-42
references.pmid: 18346159
references.citation: Arch Ophthalmol. 1999 Apr;117(4):498-503
references.pmid: 10206578
references.citation: Arch Ophthalmol. 1990 Mar;108(3):372-5
references.pmid: 2310337
references.citation: FASEB J. 1991 May;5(8):2145-54
references.pmid: 1850705
references.citation: Proc Natl Acad Sci U S A. 1989 Jul;86(13):5141-5
references.pmid: 2740348
references.citation: Exp Eye Res. 1980 Apr;30(4):401-10
references.pmid: 7449869
references.citation: Diabetes. 1979 Jan;28(1):16-9
references.pmid: 759246
references.citation: Bioessays. 1992 Jul;14(7):455-63
references.pmid: 1445287
references.citation: FASEB J. 1998 Sep;12(12):1075-95
references.pmid: 9737711
references.citation: Invest Ophthalmol Vis Sci. 1999 Mar;40(3):809-13
references.pmid: 10067990
references.citation: Diabetes. 2006 Sep;55(9):2401-11
references.pmid: 16936187
references.citation: Acta Pharmacol Sin. 2003 Jun;24(6):534-8
references.pmid: 12791179
references.citation: J Glaucoma. 2000 Apr;9(2):163-8
references.pmid: 10782626
references.citation: Angiology. 2005 Mar-Apr;56(2):173-89
references.pmid: 15793607
references.citation: Curr Pharm Des. 2007;13(26):2699-712
references.pmid: 17897014
references.citation: Surv Ophthalmol. 2002 Dec;47 Suppl 2:S253-62
references.pmid: 12507627
references.citation: BMC Health Serv Res. 2008 Jul 28;8:159
references.pmid: 18655733
references.citation: J Biol Chem. 2000 Mar 17;275(11):8051-61
references.pmid: 10713126
references.citation: Lab Invest. 2005 May;85(5):597-607
references.pmid: 15711567
references.citation: Biochem Biophys Res Commun. 2004 May 28;318(2):594-600
references.pmid: 15120641
references.citation: Ophthalmology. 2008 Nov;115(11):1869-75
references.pmid: 18584872
references.citation: Med Res Rev. 2003 Mar;23(2):117-45
references.pmid: 12500286
references.citation: Invest Ophthalmol Vis Sci. 2001 Mar;42(3):789-94
references.pmid: 11222542